{
  "documentId": "TAB‑3843",
  "title": "Engineered Cell‑Penetrating Monoclonal Antibody for Universal Inuenza Immunotherapy",
  "description": "Home » Tech » Engineered Cell‑Penetrating Monoclonal Antibody for Universal Inuenza Immunotherapy",
  "metadataJson": "{'developmentStatus': 'Pre‑Clinical', 'isAntibodiesProduct': true, 'date': '2023‑05‑17', 'patentSeriesCode' :63, 'patentApplicationNumber' :365841}",
  "section": [{
    "title": "body",
    "text": "Influenza remains a burden on public health..."
  }, {
    "title": "Clinical treatment",
    
    "text": "Clinical Treatment꞉ CPP‑mAbs against influenza NP may...",
    "metadataJson": "{'clinicalTreatment'꞉ 'CPP‑mAbs against influenza NP may...'}"
  }, {
    "text": "Current vaccines remain effective for a short time period..."
  }]
}